The epidemiology of children hospitalized with herpes zoster in Canada: Immunization Monitoring Program, Active (IMPACT), 1991-2005

Pediatric Infectious Disease Journal

Volumn 27, Issue 2, 2008, Pages 112-118

  Wootton, Susan H ^a,e   Law, Barbara ^b   Tan, Ben ^c   Mozel, Michelle ^a   Scheifele, David W ^a,f   Halperin, Scott ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c ROYAL UNIVERSITY HOSPITAL   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e UNIVERSITY OF TEXAS   (United States)

^f Vaccine Evaluation Center   (Canada)

Author keywords

Canada; Epidemiology; Herpes zoster; Pediatrics

Indexed keywords

VARICELLA ZOSTER VACCINE;

ADOLESCENT; ARTICLE; CANADA; CHILD; CHILD HOSPITALIZATION; FEMALE; HERPES ZOSTER; HUMAN; IMMUNIZATION; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; HOSPITALIZATION; IMMUNE DEFICIENCY; INFANT; PRESCHOOL CHILD; PUBLIC HEALTH; TIME;

ADOLESCENT; CANADA; CHILD; CHILD, PRESCHOOL; FEMALE; HERPES ZOSTER; HOSPITALIZATION; HUMANS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; INFANT; MALE; NATIONAL HEALTH PROGRAMS; TIME FACTORS;

EID: 40949089775     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31815948b5     Document Type: Article

References (40)

1. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol. 2006;70:S111-118.
2. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA. 2002;278:606-611.
3. Nguyen HQ, Jumaan AO, Seward JF. Decline in the mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med. 2005;352:450-458.
4. Yih WK, Brooks DR, Lett SM, et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health. 2005;5:68.
5. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis. 2005;191:2002-2007.
6. Mullooly JP, Riedlinger K, Chun C, Weinmann S, Houston H. Incidence of herpes zoster, 1997-2002. Epidemiol Infect. 2005;133:245-253.
7. National Advisory Committee on Immunization (NACI). Update on Varicella. Can Commun Dis Rep. 2004;30(ACS-1):1-28.
8. Petursson G, Helgason S, Gudmundsson S, Sigurdsson J. Herpes zoster in children and adolescents. Pediatr Infect Dis J. 1998;17:905-908.
9. Guess HA. Epidemiology of herpes zoster in children and adolescents: a population based study. Pediatrics. 1985;76:512-518.
10. Bonhoeffer J, Baer G, Muehleisen B, et al. Prospective surveillance of hospitalizations associated with varicella-zoster virus infections in children and adolescents. Eur J Pediatr. 2005;164:366 -370.
11. Feder HM, Hoss DM. Herpes zoster in otherwise healthy children. Pediatr Infect Dis J. 2004;23:451-457.
12. De Freitas D, Martins EN, Adan C, et al. Herpes zoster ophthalmicus in otherwise healthy children. Am J Ophthalmol. 2006;142:393-399.
13. Binder HR, Holland GN, Hosea S, Silverberg ML. Herpes zoster ophthalmicus in an otherwise-healthy child. JAAPOS. 2005;9:597-598.
14. Opstelten W, Zaal MJ. Managing ophthalmic herpes zoster in primary care. BMJ. 2005;331:147-151.
15. Milo-Manson G, Portwine C, Wang E. Bacterial infection complicating varicella infection: a 10-year review of hospitalized children. Can J Infect Dis. 1993;4:108-110.
16. Laupland KB, Davies HD, Low DE, et al. Invasive group A streptococ- cal disease in children and association with varicella-zoster virus infection. Pediatrics. 2000;105:e60.
17. Bjornson GL, Scheifele DW, Bell A, et al. Population-based surveillance of invasive group A streptococcal disease in British Columbia:1996 - 1998. Can J Infect Dis. 2001;12:232-236.
18. Jacobson JA, Burke JP, Benowitz BA, Clark PV. Varicella zoster and staphylococcal toxic shock syndrome in a young man. JAMA. 1983;249: 922-923.
19. Baba K. Increased incidence of zoster in normal children infected with VZV during infancy; community based follow-up study. J Pediatr. 1986;108:373-376.
20. Vossen MT, Biezeveld MH, de Jong MD, et al. Absence of circulating natural killer and primed CD8+ cells in life-threatening varicella. J Infect Dis. 2005;191:198-206.
21. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med. 1965;58:9-20.
22. Gnann JW, Whitley RJ. Herpes zoster. N Engl J Med. 2002;347:340- 346.
23. Balfour HH. Varicella zoster virus infections in immunocompromised hosts: a review of the natural history and management. Am J Med. 1988;85:68 -73.
24. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management ofherpes zoster. Clin Infect Dis. 2007;44(Suppl 1):S1-S26.
25. Berman JN, Wang M, Berry W, Neuberg DS, Guinan EC. Herpes zoster infection in the post-hematopoietic stem cell transplant pediatric population may be preceded by transaminitis: an institutional experience. Bone Marrow Transplant. 2005;37:73-80.
26. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergiloosis: clinical significance of the halo sign. Clin Infect Dis. 2007;44:373-379.
27. Venkatesh SK, Lo LL. CT appearance of varicella zoster lesions in liver and spleen in an immunocompetent patient. J Clin Virol. 2006;36:303-305.
28. Arvin AM. Varicella-zoster virus. Clin Microbiol Rev. 1996;9:361-381.
29. Gilden DH, Kleinschmidt-DeMasters BK, La Guardia JJ, Mahalingam R, Cohrs R. Neurologic complications of the reactivation of varicella zoster virus. N Engl J Med. 2000;342:635-645.
30. Jhaveri R, Sankar R, Yazdani S, Cherry J. Varicella-zoster virus: an overlooked cause of aseptic meningitis. Pediatr Infect Dis J. 2003;22:96-97.
31. Chiappini E, Calabri Giuseppe, Galli L, Salvi G, de Martino M. Varicella-zoster virus acquired at 4 months of age reactivates at 24 months and causes encephalitis. J Pediatr. 2002;140:250-251.
32. Moriuchi H, Moriuchi M, Sun CCJ, et al. Disseminated cutaneous zoster and aseptic meningitis in a previously healthy patient. J Infect. 1997; 35:183-185.
33. Furuta Y, Ohtani F, Aizawa H, Fukuda S, Kawabata H, Bergstrom T. Varicella-zoster virus reactivation is an important cause of acute peripheral facial paralysis in children. Pediatr Infect Dis J. 2005;24:97-101.
34. Chidiac C, Bruxelle J, Daures J, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis. 2001;33:62-69.
35. Tipples GA, Safronetz D, Gray M. A real-time PCR assay for the detection of varicella-zoster virus DNA and differentiation of vaccine, wild-type and control strains. J Virol Methods. 2003;113:113-116.
36. Sharrar RG, LaRussa P, Galea SA, et al. The postmarketing safety profile of varicella vaccine. Vaccine. 2001;19:916-923.
37. Quinlivan MA, Gershon AA, Nichols RA, La Russa P, Steinberg SP, Breuer J. Vaccine oka varicella-zoster virus genotypes are monomorphic in single vesicles and polymorphic in respiratory tract secretions. J Infect Dis. 2006;193:927-930.
38. Centers for Disease Control and Prevention: National, state, and urban area vaccination levels among children aged 19-35 months-United States, 2003. MMWR Morb Mortal Wkly Rep. 2004;53:658-661.
39. Heininger U, Seward JF. Varicella. Lancet. 2006;368:1365-1376.
40. Donahue JG, Choo PW, Manson JE, et al. The Incidence of herpes zoster. Arch Intern Med. 1995;155:1605-1609.